expanded access

  • June 29, 2021  

    Helping Patients Access Investigational Treatments

    With: Lea Ann Browning-McNeeSusan C. Winckler, RPh, Esq.

    For some advanced cancer patients, the best course of action may lie beyond standard treatment options. Some of these patients can enroll in clinical trials that investigate promising new treatments. But others may find their best option is to apply for individual “expanded access” to an investigational treatment. Here, our Curious Dr. George asks two leaders from the Reagan-Udall Foundation for the Food and… Read more »

  • March 9, 2020  

    Facilitating Access to Treatment for Children with Brain Cancer

    With: Leslie Jared, RN, MSN

    A Q&A with Leslie Jared, RN, MSN, Nurse Navigator at Cancer Commons. Email: leslie.jared@cancercommons.org Q: A midline glioma is a type of brain tumor that is particularly dangerous because of its nature and its location in the brain. It often afflicts children. An investigational drug called ONC201 has shown early promise in some patients whose tumors have a specific genetic mutation called H3 K27M.… Read more »

  • April 29, 2019  

    Encouraging and Paying for Clinical Trials, Right to Try, and Expanded Access: Part Three

    With: Mark Shapiro, PhD

    A Q&A with Mark Shapiro, PhD,Vice President of Clinical Development at xCures, Inc., Partner at Pharma Initiatives; mshapiro@xcures.com. This is the final installment in a three-part series in which Dr. Shapiro has shared his thoughts on the question below. Read part 1 and part 2. Q: Treatment of Americans with advanced cancer is complex and challenging and can be very expensive. Many urge greater participation of such patients… Read more »

  • April 22, 2019  

    Encouraging and Paying for Clinical Trials, Right to Try, and Expanded Access: Part Two

    With: Mark Shapiro, PhD

    A Q&A with Mark Shapiro, PhD,Vice President of Clinical Development at xCures, Inc., Partner at Pharma Initiatives; mshapiro@xcures.com. Last week, Dr. Shapiro shared his initial thoughts on the question below. Today, he discusses issues of cost and equitable access to care. Q: Treatment of Americans with advanced cancer is complex and challenging and can be very expensive. Many urge greater participation of such patients in clinical trials. In… Read more »

  • April 15, 2019  

    Encouraging and Paying for Clinical Trials, Right to Try, and Expanded Access: Part One

    With: Mark Shapiro, PhD

    A Q&A with Mark Shapiro, PhD, Vice President of Clinical Development at xCures, Inc., Partner at Pharma Initiatives; mshapiro@xcures.com Q: Treatment of Americans with advanced cancer is complex and challenging and can be very expensive. Many urge greater participation of such patients in clinical trials. In general, who pays the expenses of clinical trials? And, specifically, how are the costs for Right to Try and expanded-access approaches… Read more »

  • August 11, 2017  

    New Online Navigator Helps Patients and Doctors Access Experimental Treatments Bookmark

    Emma Shtivelman, PhD

    Excerpt:

    “When approved therapies don’t work, or stop working, for people with serious or life-threatening illnesses, it puts them in a difficult position. Some turn to clinical trials that are testing experimental treatments. But many can’t do that because they are too sick, don’t meet the requirements of the trial, or can’t afford to travel to the site of a trial. That doesn’t mean they are out of options.”

    Go to full article published by STAT on Aug 2, 2017.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.